Side-by-side · Research reference
PTD-DBMvsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED10/40 cited
BPhase 3HUMAN-REVIEWED25/54 cited
PTD-DBM
Wnt Pathway Activator · Fusion Peptide
Topical / SQ · Study-dependent
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
PTD-DBM
Survodutide
Primary target
CXXC5–Dishevelled protein-protein interaction
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
Not applicable — pathway derepression rather than receptor agonism
—
Origin
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
—
Antibody development
—
—
02Dosage Protocols
Parameter
PTD-DBM
Survodutide
Wound healing protocol
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
—
Hair regeneration protocol
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
—
Evidence basis
Animal models only (mice)
Phase 2 RCT (obesity) · Phase 3 ongoing
Co-administration
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
—
Human translation
No published human studies
—
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
PTD-DBM
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
PTD-DBM
Survodutide
Reported adverse events
None reported in animal studies
—
Wnt pathway activation risks
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
—
Long-term safety
Unknown — no chronic dosing or human data
—
Delivery vehicle effects
HA-PG hydrogel well-tolerated in mice; human translation pending
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
PTD-DBM
Survodutide
1. Wound Healing Protocol (Animal Model)
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Hair Regeneration Protocol (Animal Model)
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Combination Therapy
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage & Handling
Not disclosed in available literature. Peptide stability and storage conditions not published.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
—
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.